Indoco Remedies Approves Incorporation of Wholly Owned Subsidiary Warren Lifesciences
Indoco Remedies Ltd 路 Others (Uncategorized) 路 18 Sept 2026, 11:26 pm
Indoco Remedies Approves Incorporation of Wholly Owned Subsidiary Warren Lifesciences Indoco Remedies' Committee of Executive Directors approved the incorporation of a wholly owned subsidiary, Warren Lifesciences Private Limited, on 18th Sep'26 following name approval from the ROC, Mumbai. The new entity will operate in the pharmaceutical sector, focusing on manufacturing, developing, and selling active pharmaceutical ingredients (APIs), finished formulations, and key starting materials. Indoco Remedies will hold a 100% stake via cash subscription, with a proposed authorized and paid-up equity share capital of Rs. 1,00,000 comprising 10,000 equity shares at Rs. 10 each.
Original exchange filing (PDF)
More announcements from Indoco Remedies Ltd
- The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Aditi M Panandikar & Others 路 13 Nov 2026
- The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Suresh G Kare 路 09 Nov 2026
- The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Suresh G Kare 路 07 Nov 2026
- The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Aditi M Panandikar & Others 路 06 Nov 2026
- The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Ms. Aditi M Panandikar & Ms. Madhura Suresh Kare 路 04 Nov 2026
- The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Aditi M Panandikar & Others 路 03 Nov 2026
- Transcript of Earnings Conference Call on Unaudited Standalone and Consolidated Financial Results for the quarter and half year ended 30-09-2026 路 29 Oct 2026
- Audio recording of Earnings Conference Call on Unaudited Standalone and Consolidated Financial Results for the Quarter and Half Year Ended 30th September, 2026 路 27 Oct 2026
